The demise of fasinumab draws a line under the NGF inhibitor class, although there could be footnotes. As of a September update, AstraZeneca was still developing MEDI7352, a bispecific antibody ...
“There were equally as many sites claiming there was no evidence to support claims about cannabis and cancer, but right then, anecdotes were more than enough. When you’re given that ...